Gagnon Securities’s TherapeuticsMD TXMD Stock Holding History

Gagnon Securities’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-373	Closed	-$49K	–	97
2019 Q2	$49K	Hold	373	–	–	0.01%	97
2019 Q1	$91K	Buy	373 +20	+6%	+$5.29K	0.02%	97
2018 Q4	$67K	Hold	353	–	–	0.02%	92
2018 Q3	$116K	Buy	353 +4	+1%	+$1.23K	0.03%	99
2018 Q2	$109K	Hold	349	–	–	0.03%	96
2018 Q1	$85K	Buy	349 +1	+0.3%	+$281	0.03%	92
2017 Q4	$105K	Hold	348	–	–	0.04%	88
2017 Q3	$92K	Buy	+348	New	+$101K	0.03%	88

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gagnon Securities's TXMD Position: Q3 2019 in Review

Gagnon Securities sold out of TherapeuticsMD (TXMD) in Q3 2019, closing a stake of 373 shares — an estimated $49K sold.

Gagnon Securities first reported a position in TXMD in Q3 2017 and held it in 8 quarters. The position peaked at $116K in Q3 2018. 150 funds tracked by Wall St. Rank hold TXMD as of Q3 2019.

Gagnon Securities reported no remaining TherapeuticsMD position as of Q3 2019 after selling out during the quarter.
Gagnon Securities sold 373 TherapeuticsMD shares in Q3 2019, an estimated $49K.
Gagnon Securities first reported a position in TherapeuticsMD in Q3 2017 and held it in 8 quarters.
Gagnon Securities's TherapeuticsMD position peaked at $116K in Q3 2018.
150 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2019.

Based on Gagnon Securities's 13F filing for Q3 2019, filed 8 Nov 2019.